Andrew Kelley next COO at NextPharma
This article was originally published in Scrip
NextPharma Technologies, a contract manufacturer for the pharma, biotech and healthcare industries, has appointed Andrew Kelley chief operating officer. Mr Kelley has over 27 years' experience in the pharma industry, with a track record in manufacturing operations, having most recently served at Patheon.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.